Excretion, metabolism, and pharmacokinetics of CP-945,598, a selective cannabinoid receptor antagonist, in rats, mice, and dogs

Drug Metabolism and Disposition

Volumn 39, Issue 12, 2011, Pages 2191-2208

  Miao, Zhuang ^a   Scott, Dennis O ^a   Griffith, David A ^a   Day, Robert ^a   Prakash, Chandra ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIDE; CARBON 14; DRUG METABOLITE; OTENABANT; RIBOSE;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BILE DUCT; CATHETERIZATION; CONTROLLED STUDY; DECARBOXYLATION; DOG; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG EXCRETION; DRUG FECES LEVEL; DRUG HALF LIFE; DRUG HYDROLYSIS; DRUG METABOLISM; DRUG OXIDATION; DRUG TRANSFORMATION; DRUG URINE LEVEL; FEMALE; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; N DEETHYLATION; NONHUMAN; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; RAT; SEX DIFFERENCE; SINGLE DRUG DOSE;

ADMINISTRATION, ORAL; ANIMALS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOGS; FECES; FEMALE; MALE; MICE; MICE, TRANSGENIC; PIPERIDINES; PURINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, CANNABINOID, CB1; TANDEM MASS SPECTROMETRY;

CANIS FAMILIARIS; MUS; RATTUS;

EID: 81855173527     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.111.040360     Document Type: Article

References (28)

1. Anari MR, Creighton MD, Ngui JS, Tschirret-Guth RA, Teffera Y, Doss GA, Tang W, Yu NX, Ciccotto SL, Hobra DF Jr, Coleman JB, Vincent SH, and Evans DC. (2006) Species differences in metabolism and pharmacokinetics of a sphingosine-1-phosphate receptor agonist in rats and dogs: formation of a unique glutathione adduct in the rat. Drug Metab Dispos 34:1367-1375. (Pubitemid 44079878)
2. Arnone M, Maruani J, Chaperon F, Thiébot MH, Poncelet M, Soubrié P, and Le Fur G (1997) Selective inhibition of sucrose and ethanol intake by SR 141716, an antagonist of central cannabinoid (CB1) receptors, Psychopharmacology (Berl) 132:104-106. (Pubitemid 27303746)
3. Baillie TA, Cayen MN, Fouda H, Gerson RJ, Green JD, Grossman SJ, Klunk LJ, LeBlanc B, Perkins DG, and Shipley LA (2002) Drug metabolites in safety testing. Toxicol Appl Pharmacol 182:188-196.
4. Black SC (2004) Cannabinoid receptor antagonists and obesity. Curr Opin Investig Drugs 5:389-394.
5. Colombo G, Agabio R, Diaz G, Lobina C, Reali R, and Gessa GL (1998) Appetite suppression and weight loss after the cannabinoid antagonist SR 141716. Life Sci 63:PL113-PL117.
6. Di Marzo V (2008) CB1 receptor antagonism: biological basis for metabolic effects. Drug Discov Today 13:1026-1041.
7. Di Marzo V and Matias I (2005) Endocannabinoid control of food intake and energy balance. Nat Neurosci 8:585-589. (Pubitemid 40594198)
8. Gradolatto A, Basly JP, Berges R, Teyssier C, Chagnon MC, Siess MH, and Canivenc-Lavier MC. (2005) Pharmacokinetics and metabolism of apigenin in female and male rats after a single oral administration. Drug Metab Dispos 33:49-54. (Pubitemid 40023513)
9. Griffith DA, Hadcock JR, Black SC, Iredale PA, Carpino PA, DaSilva-Jardine P, Day R, DiBrino J, Dow RL, Landis MS, et al. (2009) Discovery of 1-[9-(4-chlorophenyl)-8-(2-chlorophenyl)-9H-purin-6-yl]-4- ethylaminopiperidine-4-carboxylic acid amide hydrochloride (CP-945,598), a novel, potent, and selective cannabinoid type 1 receptor antagonist. J Med Chem 52:234-237.
10. Hadcock JR, Griffith DA, Iredale PA, Carpino PA, Dow RL, Black SC, O'Connor R, Gautreau D, Lizano JS, Ward K, et al. (2010) In vitro and in vivo pharmacology of CP-945,598, a potent and selective cannabinoid CB(1) receptor antagonist for the management of obesity. Biochem Biophys Res Commun 394:366-371.
11. Halkier BA, Olsen CE, and Møller BL (1989) The biosynthesis of cyanogenic glucosides in higher plants. The (E)- and (Z)-isomers of p-hydroxyphenylacetaldehyde oxime as intermediates in the biosynthesis of dhurrin in Sorghum bicolor (L.) Moench. J Biol Chem 264:19487-19494. (Pubitemid 20008049)
12. Hildebrandt AL, Kelly-Sullivan DM, and Black SC (2003) Antiobesity effects of chronic cannabinoid CB1 receptor antagonist treatment in diet-induced obese mice. Eur J. Pharmacol 462:125-132. (Pubitemid 36183743)
13. Kirkham TC (2005) Endocannabinoids in the regulation of appetite and body weight. Behav Pharmacol 16:297-313.
14. Martignoni M, Groothuis GM, and de Kanter R (2006) Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. Expert Opin Drug Metab Toxicol 2:875-894. (Pubitemid 44911538)
15. Nakazawa T, Miyata K, Omura K, Iwanaga T, and Nagata O (2006) Metabolic profile of FYX-051 (4-(5-pyridin-4-yl-1H-[1,2,4]triazol-3-yl)pyridine-2- carbonitrile) in the rat, dog, monkey, and human: identification of N-glucuronides and N-glucosides. Drug Metab Dispos 34:1880-1886. (Pubitemid 44771717)
16. Paibir SG, Soine WH, Thomas DF, and Fisher RA (2004) Phenobarbital N-glucosylation by human liver microsomes. Eur J Drug Metab Pharmacokinet 29:51-59. (Pubitemid 38620510)
17. Prakash C, Chen W, Rossulek M, Johnson K, Zhang C, O'Connell T, Potchoiba M, and Dalvie D (2008) Metabolism, pharmacokinetics, and excretion of a cholesteryl ester transfer protein inhibitor, torcetrapib, in rats, monkeys, and mice: characterization of unusual and novel metabolites by high-resolution liquid chromatography-tandem mass spectrometry and 1H nuclear magnetic resonance. Drug Metab Dispos 36:2064-2079.
18. Prakash C, Cui D, Potchoiba MJ, and Butler T (2007a) Metabolism and excretion of a selective N-methyl-D-aspartate receptor antagonist, traxoprodil, in rats and dogs. Drug Metab Dispos 35:1350-1364. (Pubitemid 47121776)
19. Prakash C, Shaffer CL, and Nedderman A (2007b) Analytical strategies for identifying drug metabolites. Mass Spectrom Rev 26:340-369. (Pubitemid 46750374)
20. 1 antagonist for the treatment of obesity. Org Process Res Dev 13:186-197.
21. Richard D and Boisvert P (2006) The endocannabinoid system and its role in energy homeostasis and abdominal obesity management. Int Obes 30:S1-S2.
22. Richert L, Tuschl G, Viollon-Abadie C, Blanchard N, Bonet A, Heyd B, Halkic N, Wimmer E, Dolgos H, and Mueller SO (2008) Species differences in the response of liver drug-metabolizing enzymes to (S)-4-O-tolylsulfanyl-2-(4- trifluormethyl-phenoxy)-butyric acid (EMD 392949) in vivo and in vitro. Drug Metab Dispos 36:702-714. (Pubitemid 351468377)
23. Rinaldi-Carmona M, Barth F, Héaulme M, Shire D, Calandra B, Congy C, Martinez S, Maruani J, Néliat G, and Caput D (1994) SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 350:240-244. (Pubitemid 24268029)
24. Soine WH, Soine PJ, England TM, Graham RM, and Capps G (1994) Identification of the diastereomers of pentobarbital N-glucosides excreted in human urine. Pharm Res 11:1535-1539. (Pubitemid 24339670)
25. Tjornelund J, Hansen SH, and Cornett C (1991) New metabolites of the drug 5-aminosalicylic acid. I: N-beta-D-glucopyranosyl-5-aminosalicylic acid. Xenobiotica 21:605-612.
26. Vickers SP, Webster LJ, Wyatt A, Dourish CT, and Kennett GA (2003) Preferential effects of the cannabinoid CB1 receptor antagonist, SR 141716, on food intake and body weight gain of obese (fa/fa) compared to lean Zucker rats. Psychopharmacology (Berl) 167:103-111. (Pubitemid 36535298)
27. Wiley JL, Burston JJ, Leggett DC, Alekseeva OO, Razdan RK, Mahadevan A, and Martin BR (2005) CB1 cannabinoid receptor-mediated modulation of food intake in mice. Br J Pharmacol 145:293-300. (Pubitemid 40896074)
28. Zhao Y, Hull AK, Gupta NR, Goss KA, Alonso J, Ecker JR, Normanly J, Chory J, and Celenza JL (2002) Trp-dependent auxin biosynthesis in Arabidopsis: involvement of cytochrome P450s CYP79B2 and CYP79B3 Genes Dev 16:3100-3112. (Pubitemid 35424196)